Intense efforts are being undertaken to understand the pathophysiological mechanisms
triggered after brain ischemia and to develop effective pharmacological treatments …

In this review, we provide recent data on the role of mTOR kinase in the brain under
physiological conditions and after damage, with a particular focus on cerebral ischemia. We …

Ischemic stroke is the leading cause of serious, long-term adult disability and is associated
with sensorimotor and cognitive impairments due to neuronal degeneration. Currently …

The mammalian target of rapamycin (mTOR) is a key regulator of cell growth, autophagy,
translation, and survival. Dysregulation of mTOR signaling is associated with cancer …

Stroke is ranked as the second leading cause of death worldwide and a major cause of long-
term disability. A potential therapeutic target that could offer favorable outcomes in stroke is …

On a global basis, at least 15 million individuals suffer some form of a stroke every year. Of
these individuals, approximately 800,000 of these cerebrovascular events occur in the …

It has been reported that the mechanistic target of rapamycin (mTOR) pathway is involved in
cerebral ischemia–reperfusion injury. One of the important pathological changes during …

Traumatic brain injury (TBI) provokes primary and secondary damage on endothelium and
brain parenchyma, leading neurons die rapidly by necrosis. The mammalian target of …

Objective Whether activation or inhibition of the mTOR pathway is beneficial to ischemic
injury remains controversial. It may result from the different reaction of ischemic penumbra …

Several neuroprotection strategies shown to be effective in animal models have failed to
demonstrate efficacy in human stroke. The complexity of the molecular ischemic cascade is …